12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ilaris canakinumab regulatory update

EMA's CHMP issued a positive opinion to expand the label for Ilaris canakinumab from Novartis to include treatment of gouty arthritis. The specific indication is to treat adults with frequent gouty arthritis attacks - defined as >=3 attacks in the previous 12...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >